Astrazeneca (AZN) Research & Development (2009 - 2026)

Astrazeneca has reported Research & Development for 18 years, with the latest figure at -$4.1 billion in Q2 2026.

• On a quarterly basis, Research & Development fell 14.23% year-over-year to -$4.1 billion in Q2 2026; TTM through Jun 2026 was -$25.4 billion, a 75.46% decrease from a year earlier, with the FY2025 full-year figure at -$14.2 billion, down 4.78% from the prior year.
• Research & Development was -$4.1 billion for Q2 2026 at Astrazeneca, down from -$3.5 billion in the prior quarter.
• The five-year high for Research & Development was -$2.1 billion in Q1 2022, with the low at -$14.2 billion in Q4 2025.
• Average Research & Development over 5 years is -$3.7 billion, with a median of -$3.0 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 31.91% in 2022, then sank 204.3% in 2025.
• Over 5 years, Research & Development stood at -$2.6 billion in 2022, then dropped by 17.07% to -$3.1 billion in 2023, then tumbled by 52.2% to -$4.7 billion in 2024, then tumbled by 204.3% to -$14.2 billion in 2025, then surged by 71.52% to -$4.1 billion in 2026.
• The last three Research & Development figures came in at -$4.1 billion (Q2 2026), -$3.5 billion (Q1 2026), and -$14.2 billion (Q4 2025), per Business Quant data.